Hypertension involves endothelial dysfunction, reduced nitric oxide bioavailability, arterial stiffness, and often low-grade systemic inflammation that impairs vascular tone regulation. Peptide research targets the endothelial NO pathway, mitochondrial vascular function, and the neuroinflammatory components of elevated blood pressure.
1. BPC-157 — Endothelial NO / Vascular Repair
BPC-157 is the most extensively studied peptide for vascular health. It upregulates eNOS (endothelial nitric oxide synthase), directly increasing NO bioavailability and vascular dilation. It also promotes angiogenesis and repairs endothelial injury — addressing the structural vascular damage that contributes to chronically elevated blood pressure.
Dosing Protocol: 250–500 mcg SubQ daily. Oral BPC-157 (500 mcg) provides systemic anti-inflammatory support. Cycle: 8–12 weeks.
2. SS-31 (Elamipretide) — Mitochondrial Vascular Function
SS-31 is a mitochondria-targeting peptide that reduces reactive oxygen species (ROS) in vascular smooth muscle and endothelial cells. Oxidative stress is a major driver of endothelial dysfunction and hypertension. SS-31 restores mitochondrial efficiency in vascular tissue, reducing the ROS burden that inactivates NO and causes endothelial dysfunction.
Dosing Protocol: 1–5 mg SubQ daily. Clinical cardiovascular studies use 0.05–0.25 mg/kg IV. SubQ protocols emerging at 1–3 mg daily. Cycle: 4–8 weeks.
3. VIP — Vasodilation / Anti-Inflammatory
Vasoactive Intestinal Peptide (VIP) is a potent vasodilator that acts via VPAC1/2 receptors on vascular smooth muscle and endothelium. It reduces vascular resistance, has anti-inflammatory effects on blood vessel walls, and has demonstrated BP-lowering effects in preclinical hypertension models.
Dosing Protocol: 25–50 mcg SubQ or intranasal daily. IV VIP is used clinically in pulmonary hypertension. SubQ protocols extrapolated from clinical research.
4. Semax — Cerebrovascular / Neuroprotective
Hypertension causes significant cerebrovascular stress and contributes to cognitive decline. Semax improves cerebral blood flow autoregulation, provides neuroprotection against hypertension-induced vascular damage in the brain, and modulates the sympathetic nervous system activity that contributes to elevated arterial pressure.
Dosing Protocol: 100–300 mcg intranasal daily. Best used as an adjunct addressing the cerebrovascular and CNS components of hypertension.
BPC-157 directly restores the NO-mediated endothelial vasodilation pathway most impaired in hypertension. SS-31 eliminates the mitochondrial oxidative stress that destroys NO before it can act. VIP provides direct vasodilatory action on smooth muscle and endothelium. Semax protects the cerebrovascular bed from hypertension-mediated damage and modulates the central sympathetic drive.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).